Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2008-04-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT00667927
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
- Conditions
- Childhood Soft Tissue SarcomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood MedulloblastomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsChildhood Central Nervous System Germ Cell TumorEwing SarcomaOvarian Mixed Germ Cell TumorRecurrent Ovarian Germ Cell TumorUnspecified Adult Solid Tumor, Protocol SpecificPreviously Untreated Childhood Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00638898
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00630565
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
- Conditions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT00627666
- Locations
- 🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00623935
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
MT2004-30: Tomotherapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 8
- Registration Number
- NCT00619645
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00612716
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
- Conditions
- Interventions
- Biological: anti-thymocyte globulinDrug: busulfanDrug: cyclophosphamideDrug: mycophenolate mofetilDrug: tacrolimusGenetic: polymerase chain reactionGenetic: polymorphism analysisOther: flow cytometryOther: laboratory biomarker analysisOther: pharmacogenomic studiesOther: pharmacological studyProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 5
- Registration Number
- NCT00611351
- Locations
- 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
- Conditions
- Interventions
- First Posted Date
- 2008-01-22
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 12
- Registration Number
- NCT00598481
- Locations
- 🇮🇱
Investigational Site, Jerusalem, Israel
🇮🇹Ospedale San Raffaele, Milano, Lombardia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.